skip to content

Clinical Trials

MainTitle

Physician Focused Intervention to Improve Adherence With HIV Antiretrovirals (MAP)

This study has been completed
Sponsor
National Institute on Drug Abuse (NIDA)


Information provided by (Responsible Party)
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier
NCT00870792

First received: March 26, 2009
Last updated: January 10, 2017
Last Verified: March 2009
History of Changes
Purpose

Purpose

We hypothesized that providing physicians treating with HIV disease, at the time of a routine outpatient visit, with a detailed report describing patients' adherence with HIV antiretroviral medications, would improve the quality of the physician-patient interaction, and also patients' subsequent adherence.

Condition Intervention
HIV Infection
HIV Infections

Behavioral : Adherence report

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Health Services Research
Official Title: Physician Focused Intervention to Improve Adherence With HIV Antiretrovirals

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures

  • Antiretroviral medication adherence as assessed by electronic pill cap monitoring. [ Time Frame: 6 months ]
Secondary Outcome Measures:
  • Self-reported medication adherence [ Time Frame: 6 months ]

Enrollment: 156
Study Start Date: November 2002
Study Completion Date: February 2005
Primary Completion Date: January 2005 (Final data collection date for primary outcome measure)

Arms Assigned Interventions
Active Comparator: Received report

Behavioral: Adherence report

During the intervention phase, the data collected at the study visit were summarized in a 3-page report that was given to the provider before each intervention visit. The report included data on self-reported adherence, MEMS adherence, reminder use, beliefs about ART, reasons for missed doses, alcohol and drug use, and depression.

Placebo Comparator: Routine care
Patients receive usual, routine, care.
Behavioral: Adherence report

During the intervention phase, the data collected at the study visit were summarized in a 3-page report that was given to the provider before each intervention visit. The report included data on self-reported adherence, MEMS adherence, reminder use, beliefs about ART, reasons for missed doses, alcohol and drug use, and depression.

Eligibility

Eligibility

Ages Eligible for Study: 18 Years and older  
Sexes Eligible for Study: All  
Accepts Healthy Volunteers: No  

Criteria

Inclusion Criteria:

  • on ART
  • willing to use MEMS cap
  • speaks and reads English
  • detectable viral loads


Exclusion Criteria:
  • uses a pill box

contacts and locations

Contacts and Locations

Choosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00870792

Locations

United States, Massachusetts
Tufts Medical Center
Boston, Massachusetts, United States, 02111

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

Investigators

Principal Investigator: Ira B. Wilson, MD Tufts Medical Center
More Information

More Information


Responsible Party: Ira B. Wilson, MD, MSc, Tufte Medical Center  
ClinicalTrials.gov Identifier: NCT00870792   History of Changes  
Other Study ID Numbers: ibwadhrct88$  
Study First Received: March 26, 2009  
Last Updated: January 10, 2017  

Keywords provided by National Institute on Drug Abuse (NIDA):

HIV
antiretroviral therapy
medication adherence
Treatment Experienced

Additional relevant MeSH terms:
Infection
Communicable Diseases
HIV Infections
Acquired Immunodeficiency Syndrome

ClinicalTrials.gov processed this data on October 18, 2017
This information is provided by ClinicalTrials.gov.